Researchers explained that their findings were different from previous studies because they took a wide variety of factors, including underlying health conditions, into account.
Treatment with empagliflozin for six months was associated with several key improvements. This suggests that, yes, SGLT2 inhibitors can be recommended for HFrEF patients who don't have diabetes.